A Phase II, Open Controlled, Clinical Study of Regorafenib Combined with Envafolimab for Metastatic Gastrointestinal Stromal Tumors with Kit Gene Exon 17 Mutation That Failed Standard Treatment
Latest Information Update: 16 Jan 2025
Price :
$35 *
At a glance
- Drugs Envafolimab (Primary) ; Regorafenib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- 16 Jan 2025 New trial record